Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.

Miller MS, Pinson JA, Zheng Z, Jennings IG, Thompson PE.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):802-5. doi: 10.1016/j.bmcl.2012.11.076.

PMID:
23265896
2.

Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).

Rewcastle GW, Gamage SA, Flanagan JU, Frederick R, Denny WA, Baguley BC, Kestell P, Singh R, Kendall JD, Marshall ES, Lill CL, Lee WJ, Kolekar S, Buchanan CM, Jamieson SM, Shepherd PR.

J Med Chem. 2011 Oct 27;54(20):7105-26. doi: 10.1021/jm200688y.

PMID:
21882832
3.

Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).

Rewcastle GW, Gamage SA, Flanagan JU, Kendall JD, Denny WA, Baguley BC, Buchanan CM, Chao M, Kestell P, Kolekar S, Lee WJ, Lill CL, Malik A, Singh R, Jamieson SM, Shepherd PR.

Eur J Med Chem. 2013 Jun;64:137-47. doi: 10.1016/j.ejmech.2013.03.038.

PMID:
23644197
4.

[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.

Da Settimo F, Primofiore G, Da Settimo A, La Motta C, Taliani S, Simorini F, Novellino E, Greco G, Lavecchia A, Boldrini E.

J Med Chem. 2001 Dec 6;44(25):4359-69.

PMID:
11728182
5.
6.
7.

Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.

Harikrishnan LS, Kamau MG, Wan H, Inghrim JA, Zimmermann K, Sang X, Mastalerz HA, Johnson WL, Zhang G, Lombardo LJ, Poss MA, Trainor GL, Tokarski JS, Lorenzi MV, You D, Gottardis MM, Baldwin KF, Lippy J, Nirschl DS, Qiu R, Miller AV, Khan J, Sack JS, Purandare AV.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1425-8. doi: 10.1016/j.bmcl.2011.01.022.

PMID:
21282055
8.

New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships.

Saify ZS, Azim MK, Ahmad W, Nisa M, Goldberg DE, Hussain SA, Akhtar S, Akram A, Arayne A, Oksman A, Khan IA.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1282-6. doi: 10.1016/j.bmcl.2011.10.018.

PMID:
22204908
9.

ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.

Kong DX, Yamori T.

Acta Pharmacol Sin. 2010 Sep;31(9):1189-97. doi: 10.1038/aps.2010.150. Review.

10.

Cu-mediated N-arylation of 1,2,3-triazin-4-ones: synthesis of fused triazinone derivatives as potential inhibitors of chorismate mutase.

Shiva Kumar K, Adepu R, Sandra S, Rambabu D, Rama Krishna G, Malla Reddy C, Misra P, Pal M.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1146-50. doi: 10.1016/j.bmcl.2011.11.096.

PMID:
22189133
11.

Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.

Dao P, Jarray R, Le Coq J, Lietha D, Loukaci A, Lepelletier Y, Hadj-Slimane R, Garbay C, Raynaud F, Chen H.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4552-6. doi: 10.1016/j.bmcl.2013.06.038.

PMID:
23845217
12.

Synthesis and β-glucuronidase inhibitory potential of benzimidazole derivatives.

Khan KM, Khan M, Ambreen N, Rahim F, Naureen S, Perveen S, Choudhary MI, Voelter W.

Med Chem. 2012 May;8(3):421-7.

PMID:
22530898
13.

Synthesis and structure elucidation of novel fused 1,2,4-triazine derivatives as potent inhibitors targeting CYP1A1 activity.

El Massry AM, Asal AM, Khattab SN, Haiba NS, Awney HA, Helmy M, Langer V, Amer A.

Bioorg Med Chem. 2012 Apr 15;20(8):2624-37. doi: 10.1016/j.bmc.2012.02.041.

PMID:
22414679
14.

Synthesis, in vitro and in silico NS5B polymerase inhibitory activity of benzimidazole derivatives.

Patil VM, R GK, Chudayeu M, Gupta SP, Samanta S, Masand N, Kaushik-Basu N.

Med Chem. 2012 Jul;8(4):629-35.

PMID:
22530910
15.

Synthesis, p38 kinase inhibitory and anti-inflammatory activity of new substituted benzimidazole derivatives.

Kulkarni RG, Laufer SA, M CV, Garlapati A.

Med Chem. 2013 Feb;9(1):91-9.

PMID:
22946527
16.

Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.

Dehnhardt CM, Venkatesan AM, Chen Z, Delos-Santos E, Ayral-Kaloustian S, Brooijmans N, Yu K, Hollander I, Feldberg L, Lucas J, Mallon R.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4773-8. doi: 10.1016/j.bmcl.2011.06.063.

PMID:
21763134
18.

Inhibition of the helicase activity of the HCV NS3 protein by symmetrical dimeric bis-benzimidazoles.

Tunitskaya VL, Mukovnya AV, Ivanov AA, Gromyko AV, Ivanov AV, Streltsov SA, Zhuze AL, Kochetkov SN.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5331-5. doi: 10.1016/j.bmcl.2011.07.018.

PMID:
21821416
19.

Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.

Giordanetto F, Wållberg A, Cassel J, Ghosal S, Kossenjans M, Yuan ZQ, Wang X, Liang L.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6665-70. doi: 10.1016/j.bmcl.2012.08.101.

PMID:
23010274
20.

Indole and benzimidazole derivatives as steroid 5alpha-reductase inhibitors in the rat prostate.

Takami H, Kishibayashi N, Ishii A, Kumazawa T.

Bioorg Med Chem. 1998 Dec;6(12):2441-8.

PMID:
9925300
Items per page

Supplemental Content

Support Center